Box-Behnkenov eksperimentalni dizajn u izradi pektin-kompritol ATO 888 obloženih tableta za ciljanu isporuku mesalamina u kolon by NIRAV V. PATEL et al.
A novel oral colon-specific drug delivery system (CDDS) has been developed as one
of the site-specific drug delivery systems. This delivery system, by means of combining
one or more controlled release mechanisms, hardly releases the drug in the upper part of
the gastrointestinal (GI) tract, but rapidly releases drug in the colon following oral ad-
ministration. The necessity and advantage of CDDS have been recognized and reviewed
recently (1–3). Owing to CDDS specifically delivering the drug to the colon, many bene-
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The aim of this study was to investigate the combined
influence of 3 independent variables in the compression
coated tablet of mesalamine for ulcerative colitis. A 3-
-factor, 3-level Box-Behnken design was used to derive a
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ur plots to predict responses. The independent variables
selected were: percentage of polymers (pectin and com-
pritol ATO 888) in compression coating (X1), coating mass
(X2) and coating force (X3). Fifteen batches were prepar-
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fits would be acquired in terms of improved safety and reduced toxicity when treating
local or systemic chronic diseases. First, in treating localized colonic diseases, i.e. ulcer-
ative colitis, Crohn’s disease, constipation, etc. (1), CDDS would be advantageous when
a delay in absorption is desirable from the therapeutic point of view, as well as in the
treatment of diseases that have peak symptoms in the early morning and that exhibit cir-
cadian rhythms, such as nocturnal asthma, angina and rheumatoid arthritis (4, 5).
Pectins are non-starch, linear polysaccharides extracted from the plant cell walls.
They are predominantly linear polymers of mainly a-(1–4) linked D-galacturonic acid
residues interrupted by 1,2-linked L-rhamnose residues. These polysaccharides remain
intact in the physiological environment of the stomach and the small intestine, but are
degraded by the bacterial inhabitants of the human colon (6, 7). Being soluble in water,
pectin is not able to shield its drug load effectively during its passage through the stom-
ach and small intestine. It was found that a coat of a considerable thickness was required
to protect the drug core in simulated in vivo conditions (8, 9). Hence, the focus was shif-
ted to the development of such pectin derivatives that were less water soluble but were
degradable by the colonic microflora.
Glyceryl behenate (Compritol ATO 888) is a waxy material, originally introduced as
a lubricant for tablets, which has recently had a wide application as a sustained-release
excipient (10).
Mesalamine is an active ingredient of agents used for the long-term maintenance
therapy to prevent relapses of Crohn’s disease and ulcerative colitis (11). It is thus of tre-
mendous importance to deliver mesalamine locally in order to reduce the influence of
systemic drug absorption causing adverse effects and drug loss lowering the probability
of therapeutic success. Hence, selective delivery of mesalamine into the colon is required.
The purpose of this study was to develop and evaluate a compression coated tablet
containing mesalamine as the core and a pectin-compritol ATO 888 mixture as the coat
layer based on the GI transit time concept. In the work reported here, a Box-Behnken de-
sign was used to optimize compression coated mesalamine tablets containing pectin and
compritol ATO 888 as a compression coating polymer. The independent variables selec-
ted were: percentage of polymers (pectin and compritol ATO 888) in compression coat-
ing (X1), coating mass (X2), and coating force (X3) to evaluate their separate and com-
bined effects on the amount of drug released after 6 h (Y6), time required for 50 %
mesalamine to dissolve (t50) with pectinase and without pectinase (t50), percent of drug
released after 24 h in the presence of pectinase (Y24).
EXPERIMENTAL
Materials
Mesalamine USP was a gift from Bec Chemicals Ltd., India, pectin was obtained
from National Chemicals, India, Compritol ATO 888 was a gift from Colorcon Ltd., In-
dia. All other materials were of reagent grade.
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Methods
Preparation of 5-ASA core tablets. – Mesalamine was dry mixed with polyvinyl py-
rollidone K-30 (PVP K-30) and water was added to granulate. Wet granules were sieved
through a 1-mm screen and dried overnight at 40 °C. After adding 0.25 % magnesium
stearate as a lubricant, tablets containing 100 mg of the drug were compressed using a
Cadmach single punch tablet machine (M/S. Cadmach Machinery Co. Pvt. Ltd, India)
with 6-mm flat faced punches. Tests such as mass variation, crushing strength, friability,
thickness, and dissolution were performed on the core tablets.
Box-Behnken experimental design. – A Box-Behnken statistical design with 3 factors, 3
levels, and 15 runs was selected for the optimization study (12). The experimental de-
sign consists of a set of points lying at the midpoint of each edge and the replicated cen-
ter point of a multidimensional cube. Independent and dependent variables are listed in
Table I. The polynomial equation generated by this experimental design (using Sigma
Plot 11) is as follows:
Yi = b0 + b1X1 + b2X2 + b3X3 + b12X1X2+ b13X1X3 + b23X2X3 +
b11X12 + b22X22 + b33X32 (1)
where Yi is the dependent variable, b0 is the intercept, b1 to b33 are the regression coeffi-
cients, and X1, X2 and X3 are the independent variables selected from preliminary experi-
ments. The experimental design is summarized in Table II.
Compression coating of core tablets. – Mesalamine core tablets were placed in the 10-mm
die cavity of a laboratory hydraulic press. Depending on the design, 100 % pectin, 80 %
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X1 = percentage of polymers (pectin-compritol ATO 888)
in compression coating (%)a
60-40 80-20 100-00
X2 = coating mass (mg)b 250 350 450
X3 = coating force (kN) 20 30 40
Transformed value –1 0 1
Dependent variable
Amount of drug released after 5 h (Y5)
Dissolution rate with RC (t50)
Dissolution rate without RC (t50)
Amount of drug released after 24 h in the presence of rat cecal content (Y24 with RC)
RC – rat cecal content
a Indicates 60, 80, 100 % pectin and 40, 20, 0 % Compritol ATO 888.
b 50 mg Avicel PH 101 was incorporated in coating material to provide good compressibility.
pectin/20 % compritol ATO 888 and 60 % pectin/40 % compritol ATO 888 combinations
were used for the outer shell compression coating. Coating forces were 20, 30 or 40 kN,
and the coat mass was 250, 350 or 450 mg. To prepare coated tablets, half of the coating
material was placed in a concave die (10 mm), the core tablet was carefully positioned in
the centre of the die and the remaining coat material was added. The coat was com-
pressed around the core at different compression forces (13).
Thickness was measured with a vernier caliper (SV-03, E-Base Measuring Tools, Tai-
wan). The hardness and friability of the core tablets and of the compression-coated tab-
lets were determined using a hardness tester (Monsanto Tablet Hardness Tester, Mht-20,
Campbell Electronics, India) and the Roche Friabilator (Type EF2, Eletrolab, India), re-
spectively. The mass variation test was done by weighing 20 tablets individually, calcu-
lating the average mass and comparing the individual tablet mass to the average. Disso-
lution rates in different media were recorded on the compression coated tablets.
In vitro drug release. – Drug release studies (n = 3) were conducted under conditions
mimicking mouth-to-colon transit (14–16). The dissolution medium consisted of 900 mL
0.1 mol L–1 HCl for 2 h, replaced by 900 mL Sorensen’s phosphate buffer, pH 7.4 for 3 h,
kept at 37 ± 0.5 °C and stirred at 100 rpm, using a USP (17) dissolution apparatus type II
(TDT-06Lplus, Electrolab, India). Samples (5 mL) were withdrawn at the end of speci-
fied periods (2 h and 5 h), filtered using membrane filters (0.45 mm) and assayed spectro-
photometrically (UV-1601, Shimadzu, USA) for mesalamine at 301.5 nm in 0.1 mol L–1
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Table II. Box-Behnken experimental design with responsesa
Batch
No.









1 0 –1 –1 15.29 8.0 8.1 99.96
2 0 –1 1 0 14.4 15.3 85.69
3 0 1 –1 8.87 10.2 12.5 99.45
4 0 1 1 0 15.2 19.3 79.85
5 –1 0 –1 0 16.2 22.1 76.59
6 –1 0 1 0 19.0 26.4 65.49
7 1 0 –1 30.29 7.1 7.2 99.97
8 1 0 1 12.39 8.4 9.1 99.60
9 –1 –1 0 0 17.5 20.2 68.98
10 –1 1 0 0 18.0 20.0 70.26
11 1 –1 0 22.39 7.3 7.5 99.99
12 1 1 0 20.19 8.0 8.2 99.90
13 0 0 0 0 11.2 12.2 99.98
14 0 0 0 0 11.0 12.3 100.2
15 0 0 0 0 11.3 12.1 99.85
RC – Rat cecal content.
a All values are mean values obtained from the regression analysis.
HCl and at 334.5 nm in pH 7.4 buffer. To assess the susceptibility of the prepared me-
salamine delivery systems to the enzymatic action of colonic bacteria, drug release stud-
ies were continued in phosphate buffer saline (PBS) pH 6.8 in the absence (control) and
in the presence of rat cecal contents, since these are known to have similar contents, to
those of human intestinal microflora (18). The studies were carried out using USP disso-
lution apparatus 1 (100 rpm, 37 °C) with slight modifications. A glass beaker (250 mL)
containing 100 mL PBS pH 6.8 was immersed in the flask of the dissolution apparatus
with water at 37 ± 0.5 °C. After completing the dissolution in 0.1 mol L–1 HCl (2 h) and
phosphate buffer, pH 7.4 (3 h), baskets containing the tablets under study were im-
mersed in the PBS medium and the release study was continued for up to 24 h. Samples
(5 mL) were withdrawn at different time points (6, 8, 12 and 24 h), filtered using mem-
brane filters (0.45 mm) and assayed spectrophotometrically for mesalamine at 299 nm in
PBS pH 6.8. The same volume of fresh dissolution medium was added to restore the ini-
tial volume of the dissolution medium after each sample withdrawal. Experiments were
carried out in triplicate.
Preparation of rat cecal content medium. – Before starting experiments on animals, the
experimental protocol was subjected to the scrutiny of the Institutional Animal Ethical
Committee (IAEC) of Anand Pharmacy College, Anand, India, and was approved. Sus-
ceptibility of the compression coated tablet to the enzymatic action of colonic bacteria
was assessed by performing drug release in the medium contacting rat cecal content.
Cecal material was collected from male albino rats weighing 150–200 g maintained on a
normal diet, but the cecal enzyme production was induced by giving orally 1 mL of 2 %
(m/V) dispersion of pectin for 7 days (administered directly into the stomach using tef-
lon tubing). Thirty minutes before the commencement of drug release studies, four rats
were killed and their abdomens were opened, the cecai was isolated, ligated at both ends,
cut loose and immediately transferred into PBS previously bubbled with carbon dioxide.
The cecal bags were opened and their contents were individually weighed, pooled and
then suspended in PBS to give a final cecal dilution of 4 % (m/V).
The dissolution study was continued in 100 mL of the above made rat cecal media
after 5 h. This was done with slight modification in the experimental set-up of the USP
dissolution test apparatus. A beaker of 250 mL capacity containing 100 mL of PBS (pH
6.8) with rat cecal content was placed suitably in the dissolution vessel having water
maintained at 37 ± 0.5 °C, which in turn was kept in the water bath of the apparatus.
The study was continued from the 6th h to 24th h and the samples were withdrawn at
different intervals (6, 8, 12 and 24 h) for analysis and each time replaced with fresh PBS
containing rat cecal material bubbled with CO2. The withdrawn samples were diluted
with PBS and centrifuged. The supernatant was filtered through membrane filters (0.45
mm) and the filtrate was analyzed for mesalamine content 299 nm.
Checkpoint analysis. – A checkpoint analysis was performed to confirm the role of the
derived polynomial equation and contour plots in predicting the responses. Values of in-
dependent variables were taken at 3 points, 1 from each contour plot, and the theoretical
values of Y24 with RC were calculated by substituting the values in the polynomial
equation. Compression coated tablets were prepared experimentally at 3 checkpoints,
and evaluated for the responses.
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Optimum formula. – After developing the polynomial equations for the responses Y5,
t50 with RC and Y24 with RC with the independent variables, the formulation was opti-
mized for the response Y24 with RC. Optimization was performed to find out the level of
independent variables (X1, X2, and X3) that would yield a maximum value of Y24 with
RC with a minimum value of Y5.
RESULTS AND DISCUSSION
An attempt was made to minimize drug release in the physiological environment of
the GIT and to ensure maximum drug release in the colon by applying pectin as a com-
pression coat over the mesalamine core tablets. It was found from the in vitro dissolution
study that pectin alone cannot give a hard coat, so Compritol ATO 888 was added be-
cause it retards the release until polymer solubilization takes place at the higher pH of
the colon. From Table II it was found that independent variable, X1 (percentage of poly-
mers, in compression coating) at high level medium level of (80-20) (100-0) could the re-
lease drug into the physiological stomach and intestine environment.
Data analysis
All batches of compression coated tablets were evaluated for Y5, t50 with RC and
Y24 with RC. Transformed values of all the batches, along with their results are shown in
Table II. Formulations 2, 4, 5, 6, 9, 10, 13, 14 and 15 had the lowest Y5 (0 %). Table III
shows the observed and predicted values with residuals and percent error of responses
for all batches. The Y5 (dependent variable) obtained at various levels of the 3 independ-
ent variables (X1, X2, and X3) was subjected to multiple regression to yield a second-or-
der polynomial equation (full model):
Y5 = 10.66 X1 – 1.07 X2 – 5.26 X3 – 0.55 X1X2 – 4.475 X1X3 +
1.61 X2X3 + 7.63 X12 + 3.0 X22 + 3.03 X32 (2)
The value of the coefficient of determination (R2) of Eq. (2) was found to be 0.9952,
indicating good fit. The Y5 values measured for the different batches showed wide varia-
tion (i.e., values ranged from a minimum of 0 to a maximum of 30.29). The results clearly
indicate that the Y5 value is strongly affected by the variables selected for the study. This
is also reflected in the wide range of values for coefficients of the terms of Eq. (2) The
main effects of X1, X2, and X3 represent the average result of changing 1 variable at a
time from its low level to its high level. The interaction terms (X1X2, X1X3, X2X3, X12,
X22, and X32) show how Y5 changes when 2 variables are simultaneously changed. The
negative coefficients for 2 independent variables, X2 and X3, indicate an unfavorable ef-
fect on Y5, while the positive coefficients for the interactions between 2 variables X2X3
indicate a favorable effect on Y5. The significance level of coefficients b2 and b12 was
found to be p = 0.0510 and 0.4, respectively, hence it was omitted from the full model to
generate the reduced model. Coefficients b1, b3, b13, b23, b11, b22 and b33 were found to be
significant at p < 0.05; hence they were retained in the reduced model. The reduced
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model was tested in portions to determine whether the coefficients b2 and b12 contribu-
ted significant information for the prediction of Y5. The results of testing the model in
portions are shown in Table III.
The critical value of F = 5.79 (p = 0.05) is higher than the calculated value (F = 3.69).
It may be concluded that the interaction terms b2 and b12 do not contribute significantly
to the prediction of Y5 and the low coefficients for these terms in Eq. (2) indicate that
these terms contribute the least to the prediction of Y5. Hence, these terms are omitted
from the full model to obtain a reduced second-order polynomial equation [Eq. (3)] by
multiple regressions of Y5 and the significant terms (p < 0.05) of Eq. (2):
Y5 = 10.66 X1 – 5.26 X3 – 4.475 X1X3 + 1.61 X2X3 + 7.63 X12 + 3.0 X22 + 3.03 X32 (3)
This implies that the effects of the percentage of polymers (pectin-compritol ATO
888) in compression coating and the coating force are significant, as it is evident from
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Table III. Testing the model in portionsa
Regression Df
For Y5 Fcalc = 3.697
Ftable = 5.79SS MS R2 p
FM 9 1487.09 165.23 0.9952 2.89E-05 Df = (2,5)
RM 7 1476.59 210.94 0.9882 3.24E-06
Residual
FM 5 7.12 1.42
RM 7 17.62 2.51
Regression Df
For t50 (with RC) Fcalc = 3.3841
Ftable = 4.82SS MS R2 p
FM 9 237.65 26.40 0.9708 0.0025 Df = (8, 5)
RM 1 199.00 199.00 0.8129 0.0000043
Residual
FM 5 7.14 1.428
RM 13 45.80 3.52
Regression Df
For Y24 (with RC) Fcalc = 4.31
Ftable = 4.88SS MS R2 p
FM 9 2539.88 282.20 0.9727 0.0021 Df = (7, 5)
RM 2 2110.51 1055.25 0.8083 0.000049
Residual
FM 5 71.13 14.23
RM 12 500.50 41.70
their high coefficients. The results of multiple linear regression analysis (reduced model)
reveal that, on increasing the percentage of polymers (pectin-compritol ATO 888) in com-
pression coating, an increase in Y5 is observed; the coefficient b1 bears a positive sign.
Time required for 50 % mesalamine to dissolve with RC (t50) (h) was found to be in
the range of 7.0 to 19.0 h. A polynomial equation was also developed for time required
for 50 % mesalamine to dissolve with RC (t50) (h):
t50 (with RC) = 11.17 – 4.99 X1 + 0.52 X2 + 1.94 X3 + 0.05 X1X2 –
0.375 X1X3 – 0.35 X2X3 + 1.13 X12 + 0.40 X22 + 0.37 X32 (4)
The value of R2 from Eq. (4) was found to be 0.9708, indicating good fit. Among the
independent variables selected and their interactions, only X1 was found to be signifi-
cant (p < 0.05), indicating a major contributing effect of X1 on t50 with RC. The negative
coefficients for independent variable X1 indicate an unfavorable effect on t50 with RC,
while the positive coefficients for independent variables X2 and X3 indicate a favorable
effect on t50 with RC. The interactions between two variables X1X2 indicate a favorable
effect on t50 with RC. The coefficient b1 was the only coefficient found to be significant
(p < 0.05); hence it was retained in the reduced model. The reduced model was tested in
portions to determine whether the entire coefficient contributes significant information
for the prediction of t50 with RC. The results testing the model in portions are shown in
Table III.
The critical value of F = 4.82 (p = 0.05) is again higher than the calculated value (F =
3.3841). It may be concluded that none of the interaction terms except b1 contribute sig-
nificantly to the prediction of t50 with RC and the low coefficients for these terms in Eq.
(2) indicate that these terms contribute the least to the prediction of t50 with RC. Hence,
these terms were omitted from the full model to obtain a reduced first-order binomial
Eq. (5):
t50 (with RC) = 12.18 – 4.99 X1 (5)
This implies that the main effect of the percentage of polymers (pectin-compritol
ATO 888) in compression coating is significant, as it is evident from the high coefficient.
The results of multiple linear regression analysis (reduced model) reveal that, on in-
creasing the percentage of polymers (pectin-compritol ATO 888) in compression coating,
a decrease in t50 with RC is observed; the coefficient b1 bears a negative sign. It was con-
cluded that if at higher level of X1 (pectin-compritol ATO 888: 100-0), time for 50 % of
drug released compression coated tablets was decreased. Thus, it was concluded that
compritol ATO 888 could control drug release from the compression coated tablets. It
was concluded from Table II that at medium level of X1, 50 % drug was released in 8 to
14 h. From Eq. (4), it was found that coefficients for X2 and X3 were positive i.e. if the
coat mass and compression force were increased, time for 50 % drug release increased. It
was concluded that the coat mass and compression force can also control drug release
from compression coated tablets. Y24 (with RC) was found to be in the range of 65.0 to
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100.0 %. A polynomial equation was also developed for the amount of drug released af-
ter 24 h in the presence of rat cecal content (Y24 with RC):
Y24 (with RC) = 100.01 + 14.76 X1 – 0.645 X2 – 5.67 X3 – 0.34 X1X2 +
2.68 X1X3 – 1.33 X2X3 –10.52 X12 – 4.70 X22 – 4.07 X32 (6)
The value of R2 from Eq. (6) was found to be 0.9727, indicating good fit. Among the
independent variables selected and their interactions, only X1 and X12 were found to be
significant (p < 0.05), indicating a major contributing effect of X1 on Y24 (with RC). The
negative coefficients for independent variables X2 and X3 indicate an unfavorable effect
on Y24 (with RC), but the value of coefficient of X2 was much lower than X3, so X3 alone
has a major but unfavorable effect on Y24. The interactions between variables X1X3 indi-
cate a favorable effect on Y24 (with RC). Coefficients b1 and b11 were found to be signifi-
cant at p < 0.05; hence they were retained in the reduced model. The reduced model was
tested in portions to determine whether the entire coefficient contributes significant in-
formation for the prediction of Y24 with RC. The results of testing the model in portions
are shown in Table III.
The calculated value (F = 4.31) was lower than the critical value (F = 4.88), leading
to the conclusion that none of the interaction terms except b1 and b11 contribute signifi-
cantly to the prediction of Y24 with RC. Hence, these terms were omitted from the full
model to obtain a reduced second-order polynomial Eq. (7):
Y24 (with RC) = 94.99 + 14.76 X1 – 9.90 X1X1 (7)
This implies that the main effect of the percentage of polymers (pectin-compritol
ATO 888) in compression coating is significant, as it is evident from the high coefficients.
The results of multiple linear regression analysis (reduced model) reveal that, on in-
creasing the percentage of polymers (pectin-compritol ATO 888) in compression coating,
an increase in Y24 (with RC) is observed; the coefficient b1 bears a positive sign. It was
concluded that at higher level of X1 (pectin-compritol ATO 888: 100-0), 100 % of drug
was released from compression coated tablet within 24 h. From Table II it was concluded
that at low level of X1, 100 % drug was not released in 24 h. From Eq. (6) it was found
that coefficients for X2 and X3 were negative, i.e., if coat mass and compression force
were increased, drug release was decreased. From Table II it was concluded that me-
dium level of X1 (pectin-compritol ATO 888: 80-20) was selected for targeting compres-
sion coated tablets into colon without releasing the drug in the stomach and intestine. It
was also concluded that compression force can also affect drug release during its transit
from mouth to colon but not coat mass. Medium level of compression force was selected
(formulations 13–15) because around 100 % drug was released in 24 h.
The relationship between the dependent and independent variables was further
elucidated by constructing contour plots. The effects of X1 and X3 with their interactions
on Y5 at a fixed level of X2 (medium level) are shown in Fig. 1.
The plots were found to be nonlinear, indicating a nonlinear relationship between
X1 and X3. It was determined from the contour plot that a lower value of Y5 (0 %) could
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Fig. 1. Contour plot showing the effect of percentage of polymers (pectin-compritol ATO 888) in
compression coating (X1) and coating force (X3) on the percent of drug released after 5 h (Y5).














































Fig. 2. Contour plot showing the effect of percentage of polymers (pectin-compritol ATO 888) in
compression coating (X1) and coating mass (X2) on the percent of drug released after 5 h (Y5).
be obtained with an X1 level range from –0.1 to 0.0 and an X3 level range from 0.0 to 1.0.
It is evident from the contour that the low level of both X1 and X3 favors Y5. When the
coefficient values of the two key variables, X1 and X3, were compared, the value of vari-
able X1 (b1 = 10.66) was found to be higher, indicating that it contributed the most to pre-
dicting the Y5. The negative effects of X3 on Y5 may be attributed to the coating force of
compression coated tablets and it was concluded that at higher coating force, core tab-
lets remain intact up to 5 h. Fig. 2 shows the contour plot drawn at a 0 level of X3. The
contours of all Y5 values were found to be curvilinear and indicated that a low value of
Y5 (0 %) can be obtained for a combination of the two independent variables, the X1 le-
vel in the range of –1.0 to –0.3, and the X2 level in the range of 0.0 to 1.0.
The effects of X1 and X3 with their interaction on Y24 at a fixed level of X2 (medium
level) are shown in Fig. 3. The plots were found to be nonlinear, indicating a nonlinear
relationship between X1 and X3. It was determined from the contour plot that a higher
value of Y24 (100 %) could be obtained with an X1 level range from 0.0 to 1.0 and an X3
level range from –1.0 to 0.0. It is evident from the contour that the medium level of both
X1 and X3 favors Y24.
The effects of X1 and X2 with their interaction on Y24 at a fixed level of X3 (medium
level) are shown in Fig. 4. The plots were found to be nonlinear indicating a nonlinear
relationship between X1 and X2. It was determined from the contour plot that a higher
value of Y24 (100 %) could be obtained with an X1 level of 1.0 and an X2 level range from
–1.0 to 0.0. It is evident from the contour that the medium level of both X1 and X2 favors
Y24.
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Fig. 3. Contour plot showing the effect of percentage of polymers (pectin-compritol ATO 888) in
compression coating (X1) and coating force (X3) on the percent of drug released after 24 h in the
presence of rat cecal content (Y24 with RC).
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Fig. 4. Contour plot showing the effect of percentage of polymers (pectin-compritol ATO 888) in
compression coating (X1) and coating mass (X2) on the percent of drug released after 24 h in the



















































Fig. 5. Contour plot showing the effect of coating mass (X2) and coating force (X3) on the amount of
drug released after 24 h in the presence of rat cecal content (Y24 with RC).
The effects of X2 and X3 with their interaction on Y24 at a fixed level of X1 (medium
level) are shown in Fig. 5. From Figures 1–5, the following observations can be made. All
contour plots for a high value of Y5 and Y24 were found to be nonlinear. This signifies
that there is no direct linear relationship between the selected independent variables. A
low value of Y5 can be obtained for low and medium levels of X1 but the low level of X1
does not favor Y24. Thus, medium level of X1 was selected. Similarly, at higher level of
X3, the drug was not released up to 24 h, so the medium level of X3 was selected.
Table IV shows the observed and predicted values with residuals and percent error
of responses for all batches for Y24 with RC.
Checkpoint analysis
Three checkpoint batches were prepared and evaluated for Y24, as shown in Table V.
Results indicate that the measured Y24 values were as expected. When measured Y24 val-
ues were compared with predicted Y24 values using Student’s t-test, the differences were
found to be not significant. Thus, we can conclude that the obtained mathematical equa-
tion is valid for predicting Y24.
Optimum formula
After studying the effect of the independent variables on the responses, the levels of
variables that give the optimum response were determined. It is evident from the poly-
nomial equation and contour plots (Figs. 4 and 5) that a high level of X1 could not target
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1 99.96 96.12 3.84 3.84
2 85.69 87.64 –1.96 2.28
3 99.45 97.49 1.96 1.97
4 79.85 83.69 –3.85 4.82
5 76.59 78.91 –2.32 3.03
6 65.49 62.41 3.08 4.70
7 99.97 103.07 –3.1 3.10
8 99.60 97.29 2.31 2.32
9 68.98 70.33 –1.36 1.96
10 70.26 69.72 0.54 0.76
11 99.99 100.53 –0.54 0.55
12 99.90 98.56 1.34 1.34
13 99.98 100.01 –0.03 0.03
14 100.20 100.01 0.19 0.19
15 99.85 100.01 –0.16 0.16
the compressed tablet to the colon and a low level of X1 could not release the drug in 24 h.
Hence, the medium level was selected as optimum for X1, since up to this level a low
value of Y5 (0 %) can be obtained. The optimum formulation is one that targets compres-
sed tablets to the colon (Y5 = 0 %), 50 % of the drug releases within 8 h after reaching the
colon (t50 with RC = 11 h) and the total amount of drug releases within 24 h in a con-
trolled manner, Y24 (with RC) = 100 %. Using a computer optimization process and the
contour plot shown in Fig. 8, we selected levels of 0.2 and –0.15 for both X2 and X3, res-
pectively, which give the theoretical values of 0 % and 100.47 % for Y5 and Y24, respec-
tively. Hence, a 0 level (80-20) for percentage of polymers (pectin-compritol ATO 888) in
compression coating (X1), a 0.2 level of coating mass (X2), and a –0.15 level of coating
force (X3) were selected as optimal. To prove this, a fresh formulation was prepared at
optimum levels of the independent variables, and the resultant colon targeted compre-
ssed tablets were evaluated for the responses. The observed values of Y5 and Y24 with
RC were found to be 0.7 % and 99.99 %, respectively, which were in close agreement
with the theoretical values.
CONCLUSIONS
Optimization of a colon targeted formulation is a complex process that requires a
large number of variables and their interactions to be considered. The present study con-
clusively demonstrates the use fulness of a Box-Behnken design in optimization of colon
targeted formulations. The derived polynomial equations and contour plots aid in pre-
dicting the values of selected independent variables for preparation of the optimum con-
trolled release colon targeted formulation of mesalamine with desired properties.
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S A @ E T A K
Box-Behnkenov eksperimentalni dizajn u izradi pektin-kompritol ATO 888
oblo`enih tableta za ciljanu isporuku mesalamina u kolon
NIRAV V. PATEL, JAYVADAN K. PATEL i SHREERAJ H. SHAH
Cilj rada bio je ispitati utjecaj tri nezavisne varijable u oblo`enim tabletama mesala-
mina za ulcerativni kolitis. 3-faktorijalni, Box-Behnkenov dizajn na 3 nivoa upotrijebljen
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je za dobivanje polinomske jednad`be drugog reda i konstruiranje konturnih krivulja za
predvi|anje odgovora. Izabrane nezavisne varijable bile su: udio polimera (pektin i kom-
pritol ATO 888) u oblaganju kompresijom (X1), masa tvari za oblaganje (X2) i sila za ob-
laganje (X3). Izra|eno je petnaest pripravaka kojima su ispitani sljede}i parametri: udio
lijeka oslobo|enog nakon 5 h (Y5), vrijeme potrebno za otapanje 50 % mesalamina (t50)
uz i bez prisutnosti crijevnog sadr`aja {takora (RC), postotak oslobo|enog lijeka tijekom
24 h u prisutnosti crijevnog sadr`aja (Y24 uz RC). Transformirane vrijednosti nezavisnih
i zavisnih varijabla podvrgnute su vi{estrukoj regresijskoj analizi da se odredi polinom-
ska jednad`ba drugog reda potpunog modela. F vrijednost izra~unata je da se potvrdi
izostavljanje nezna~ajnih ~lanova iz jednad`be potpunog modela. Kompjutorski optimi-
zirani proces i krivulje predvi|aju nezavisne varijable X1, X2 i X3 (0, 0,2, odnosno –0,15)
za ciljanu isporuku u kolon i ukupni postotak lijeka oslobo|enog tijekom 24 h.
Klju~ne rije~i: mesalamin, oblo`ene tablete, ciljana isporuka u kolon, osloba|anje lijeka, kompritol
ATO 888, pektin, Box-Behnkenov eksperimentalno dizajniranje
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